The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Physical activity levels have a significant association with a reduced incidence of restrictive spirometry patterns (RSP).

Research findings increasingly indicate close associations between autoimmune thyroid disease and rheumatic disease.

The global age-standardized incidence and prevalence rates of RA increased from 1990 to 2021 while mortality rates declined.

More than one-third of patients with SSc screened positive for self-reported depression, with GI involvement identified as the most significant predictor.

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.